GERMANTOWN, Maryland and HILDEN, Germany, January 11, 2011 - QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.
GERMANTOWN, Maryland and DES PLAINES, Illinois, October 12, 2010 - QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Abbott (ABT: NYSE) today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada.
VENLO, The Netherlands, September 1, 2010 - QIAGEN N.V.
VENLO, The Netherlands, February 8 - QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.
VENLO, Netherlands - QIAGEN donates one million tests to expand access to HPV screening in the world's poorest countries Results from an eight-year trial involving more than 130,000 women published today in The New England Journal of Medicine (NEJM) demonstrate that in low-resource settings a single round of HPV testing significantly reduces the numbers of advanced cervical cancers and deaths, compared with Pap (cytology) testing or visual inspection with acetic acid (VIA).